2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  3. Antibody-Drug Conjugates (ADCs) EGFR
  4. Trastuzumab deruxtecan

Trastuzumab deruxtecan  (Synonyms: T-DXd; DS-8201; DS-8201a)

Cat. No.: HY-138298A Purity: 99.50%
COA
SDS
Handling Instructions Technical Support

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

For research use only. We do not sell to patients.

CAS No. : 1826843-81-5

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Trastuzumab deruxtecan:

Trastuzumab deruxtecan Related Antibodies

Top Publications Citing Use of Products

    Trastuzumab deruxtecan purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255.  [Abstract]

    Trastuzumab deruxtecan (1 μg/mL; 120 h). H2170 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.

    Trastuzumab deruxtecan purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255.  [Abstract]

    Trastuzumab deruxtecan (0-10 μg/mL; 72 h). JFCR-007 Luc-ZsG-positive cells were treated with T-DXd for 72 h in each co-culture conditions. Cell viability was measured by ONE-Glo Luciferase Assay.

    Trastuzumab deruxtecan purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255.  [Abstract]

    Trastuzumab deruxtecan (0-10 μg/mL; 120 h). The indicated cells were treated with serially diluted T-DXd for 120 h in a 2D culture condition.

    Trastuzumab deruxtecan purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255.  [Abstract]

    JFCR-007 was treated with or without T-DXd (10 μg/mL) for 120 h in spheroid condition.

    Trastuzumab deruxtecan purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Jun 11:725:150255.  [Abstract]

    Trastuzumab deruxtecan (1 μg/mL; 120 h). JFCR-007 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.

    View All EGFR Isoform Specific Products:

    View All Isoforms
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].

    In Vitro

    Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM[2].
    Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2-negative MDA-MB-468 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Trastuzumab deruxtecan Related Antibodies
    In Vivo

    Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition[2].
    Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    153000 (average)

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    [Trastuzumab deruxtecan]
    Shipping

    Shipping with dry ice.
    Storage

    -80°C, protect from light
    Solvent & Solubility
    In Vitro: 

    H2O : ≥ 20 mg/mL

    *"≥" means soluble, but saturation unknown.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 50 mg/mL; Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.68%

    SDS (251 KB)

    COA (232 KB) Others (236 KB) SEC-HPLC (233 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Trastuzumab deruxtecan Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Trastuzumab deruxtecan1826843-81-5T-DXd DS-8201 DS-8201aDS8201DS 8201DS-8201Antibody-Drug Conjugates (ADCs)EGFRAntibody-Drug ConjugatesEpidermal growth factor receptorErbB-1HER1epidermal growth factorHER2antibody-drugconjugateADCantitumorcancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Trastuzumab deruxtecan
    Cat. No.:
    HY-138298A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.